Grant Search

Cancer Type

Keyword Search  

Categories

Grant Amount
>=

<=





Results: 192

Protein degradation as a strategy to target mutant WIP1 in ...

Close to 20% of Diffuse Intrinsic Pontine Gliomas (DIPGs) harbor a mutation in a gene called PPM1D that leads to expression of a truncated form of a protein called WIP1. We have found PPM1D-mutant DIPG cells to require expression of WIP1, rendering it an attractive therapeutic target for these ...

The current situation of childhood brain tumor long-term survivors in ...

Central nervous system tumors, represent the highest mortality rate of all childhood malignancies, Nevertheless, the number of survivors of pediatric Brain tumors continues to increase. Gradually improving survival rates and a growing population of long-term survivors have expanded the focus of research, Increased attention has been given to late ...

Epigenetic Targeted Therapy and Resistance in AT/RT

Pediatric rhabdoid tumor in the brain, atypical teratoid/rhabdoid tumor (AT/RT), is a highly malignant brain tumor that has a very poor prognosis despite aggressive treatment. The development of new, effective therapeutic approaches for AT/RT has been hindered by a lack of specific therapeutic targets. It is necessary ...

Targeting Glycolysis for Inhibition of Tumor Growth in Pediatric Brain ...

Pediatric brain tumors have limited responses to conventional therapeutic option and high mortality rates. Novel approaches to treat these and other forms of cancer involve targeting metabolic mechanisms of cancer cells from which they derive energy. These include aerobic glycolysis or the Warburg effect; named after Otto Warburg who first ...

Precision Therapy to Overcome Chemoresistance in Pediatric Glioblastoma

Glioblastoma (GBM) remains one of the most aggressive and lethal forms of cancer. Despite the best available treatment options including surgical resection, radiotherapy, and chemotherapy, prognosis is poor in glioblastoma, with a median overall survival of 14 months.1Currently, temozolomide (TMZ) is the preferred chemotherapeutic drug in the treatment of GBM ...